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Severe, early-onset fetal growth restriction is 
characterised by a fetus presenting at a gestational age 
at the borderline of viability, which is extremely small 
for gestational age by ultrasonic biometry, and who 
exhibits other signs of utero-placental insufficiency, such 
as abnormal patterns of uterine or umbilical blood flow. 
Following diagnosis, no disease-modifying therapy is 
available other than medically indicated delivery, which 
carries a high risk of neonatal death or, if the infant 
survives, severe neurodisability in later life. Conversely, 
expectant management carries a substantial risk of 
intrauterine fetal death. Balancing of these conflicting 
risks is a day-to-day element of practice in maternal–
fetal medicine. Practitioners look to a future of disease-
modifying therapies other than delivery. 
Unfortunately, the STRIDER trial1 suggests that one 
of the promising candidates, sildenafil, is very unlikely 
to offer hope in this dismal situation. The study was 
powered to detect a 7-day prolongation in pregnancy. 
No difference was found in the median randomisation 
to delivery interval between the placebo group (18 days 
[IQR 8–28]; p=0·23) and the treatment group (17 days 
[7–24]), and in reality, the 95% CI (2·7days, 95% CI 
–1·3 to 6·8; p=0·19) indicates that the best one could 
expect is a 1·3 day prolongation. 
The investigators recruited women with a small for 
gestational age fetus plus abnormal umbilical artery 
Doppler flow velocimetry, manifested as absent or 
reversed end-diastolic flow. Women were eligible 
from 22 weeks of gestational age onwards. These 
characteristics identify participants in the STRIDER trial1 
as higher risk than women recruited to the TRUFFLE 
study,2 a multicentre, randomised, controlled trial of 
different forms of fetal assessment in the context of 
early-onset fetal growth restriction, which reported its 
primary outcome in 2015. The minimum gestational 
age for recruitment to the TRUFFLE study2 was 26 weeks. 
Moreover, TRUFFLE also included women with forward 
end-diastolic flow in the umbilical artery, because the 
inclusion criteria used a pulsatility index more than the 
95th percentile. The higher risk nature of the STRIDER 
group1 is manifested in higher rates of perinatal death: 
about 45% of the STRIDER cohort1 died in utero or in 
the neonatal period compared with about 8% in the 
TRUFFLE study.2
Participants in the STRIDER trial1 were randomly 
assigned to receive sildenafil 25 mg three times a day or 
a placebo. Subsequent fetal assessment was based on 
the TRUFFLE protocol.2 The primary outcome for the trial 
was delay of delivery but changes in fetal assessment 
in relation to exposure to the drug or placebo were also 
analysed, plus a wide range of secondary outcomes. The 
active treatment was associated with deterioration in 
indices of fetal wellbeing, specifically in the ductus venosus 
a-wave (p=0·019). Examination of a range of secondary 
outcomes showed no better outcomes in the pregnant 
women treated with sildenafil than those women treated 
with placebo. In short, the trial was resoundingly negative.
Other candidate disease-modifying treatments are 
being developed for both early-onset fetal growth 
restriction and the closely related and commonly co-
existing condition of early-onset severe pre-eclampsia. 
Sildenafil was an exemplar of one approach to identifying 
novel therapies, namely, the repurposing of drugs 
licensed for other conditions. This approach involves 
matching the pathophysiology of severe, early-onset 
fetal growth restriction to the pharmacology of existing 
drugs. Other candidates have been ident ified for early-
onset fetal growth restriction or pre-eclampsia, or both, 
including proton-pump inhibitors,3 metformin,4 and 
pravastatin.5 One positive element to take from the 
STRIDER trial1 is that it has taken just 3 years from first 
recruitment to publication. Moreover, the trial is part of 
an international network (Global Obstetric Network) and 
multiple trials have been established internationally using 
comparable protocols to allow, ultimately, an individual 
patient meta-analysis. Although it is disappointing 
that these efforts have yielded a negative result on this 
occasion, the existence of such a network will be crucial 
for the evaluation of future candidate treatments. 
An alternative approach to repurposing of existing drugs 
is the development of novel treatments. Target develop-
ment is also based on our understanding of the disease 
mechanism. In the case of pre-eclampsia, the available 
model is that the hypoxic placenta releases the soluble 
form of the fms-like tyrosine kinase 1 receptor (sFLT1) into 
the mother’s circulation where it binds and inactivates pro-
angiogenic growth factors, such as placenta growth factor 
(PlGF) and vascular endothelial growth factor A (VEGF-A).6 
PlGF and VEGF-A are thought to be essential for the 
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Status epilepticus (SE) is the most common neurological 
emergency encountered in childhood; therefore, care 
providers need to be aware of the acute and chronic impli-
cations to accurately counsel patients and their families.1 
The umbrella diagnosis of SE includes numerous subtypes: 
electrographic SE, convulsive SE, focal SE with impaired 
consciousness, and absence SE. The most recent guidelines 
from the International League Against Epilepsy (ILAE) 
provide two convulsive SE timepoints: the time at which 
continuous seizure activity requiring the administration 
of an emergency medication is likely (5 min), and the time 
at which a continued seizure might lead to permanent 
neuronal damage (30 min).2 Unfavorable short-term 
outcomes after SE, such as in-hospital mortality and 
maintenance of normal endothelial function. Hence, the 
model links placental dysfunction to maternal endothelial 
dysfunction, the cardinal feature of pre-eclamspia. 
Genome-wide association studies and exome sequencing 
data for pre-eclampsia have identified variants associated 
with the FLT1 gene and such observations strongly support 
a causal role for sFLT1 in the cause of pre-eclampsia.7,8 This 
role of elevated sFLT1 raises the possibility of targeted 
therapies to manipulate the system. One approach is to use 
therapeutic apheresis to remove sFLT1 from the serum of 
women with severe, early-onset pre-eclampsia.9 Another 
targeted approach to novel therapies, which manipulate 
angiogenic pathways, is the use of gene therapy, which 
is being developed for severe, early-onset fetal growth 
restriction. Adenoviral vectors with the VEGF gene are 
delivered to the uterine artery, inducing both short-term 
changes in smooth muscle contraction and promoting 
long-term changes through vascular remodelling.10 The 
hope is that correcting maternal underperfusion of the 
placenta will enhance placental transfer, correcting a key 
factor in the pathogenesis of the disease. 
Although early-onset fetal growth restriction and 
pre-eclampsia are both rare, the huge lifelong costs of 
these outcomes justify a substantial focus of resources 
on research. Doing nothing will result in persistently 
high rates of stillbirth and cohorts of impaired children, 
with resulting societal and economic costs. But 
progress depends on strong candidate therapies and 
these therapies in turn depend on knowledge of the 
mechanisms of diseases related to the placenta. Very 
basic questions remain unanswered. Why do the risks of 
these conditions vary according to the sex of the fetus? 
Why is it that placental dysfunction can lead to pre-
eclampsia without fetal growth restriction, fetal growth 
restriction without pre-eclampsia, or the coexistence of 
both conditions? Hence, basic and translational research 
are the vital prerequisites to trials such as STRIDER. As 
the present study shows, however effective the network 
and trial design, interventional studies will only be as 
useful as the candidate drugs they evaluate.
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